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52 Chapter 4. Interlaboratory QC Programme
To the Editor
Tuberculosis (TB) remains a major global health problem. Inadequate exposure
to TB drugs constitutes one of the main factors underlying suboptimal treatment
response and development of resistance, as evidenced by results from the in vitro
hollow fibre model [1], clinical studies on relationships between drug concentra-
tions and response [2–5], a pharmacogenetic trial [6], and findings of a recent
meta-analysis [7].
More specifically, these concentration-effect evaluations suggest that clinicians
should prescribe higher doses of rifampicin [2, 5], use acetylator status to determine
the dose of isoniazid [6, 7], and that higher doses and exposures to pyrazinamide
may increase efficacy [4, 5].
Clearly such studies also underline the relevance of careful concentration-effect
evaluations during the development of new TB drugs that eventually will be applied
by clinicians all over the world.
Finally, these studies support the concept of therapeutic drug monitoring (TDM)
of TB drugs as applied by clinicians and pharmacists in selected centres around
the world [8–10]. In contrast to administering the same fixed dose to all patients,
TDM is seeking to individualize drug doses, guided by measurement of serum (or
plasma) drug concentrations.
Both pharmacokinetic evaluations in academia and in drug development pro-
grammes and the use of TDM require the application of analytical methods for
TB drugs. Intralaboratory (internal) method validation and intralaboratory quality
control (QC) procedures, such as validation of equipment and qualification of
technicians, should ensure that these methods have sufficient accuracy, precision
and specificity. In addition, participation in an interlaboratory (external) QC (or
proficiency testing) programme is an essential component of quality assurance
and also provides evidence of laboratory competence for clinicians, researchers,
accrediting bodies and regulatory agencies [11].
It is worth noting that (semi)automated immuno-assays are not available for meas-
urement of TB drugs. TB drugs are being measured by so called chromatographic
assays that have to be developed and validated within each laboratory, sometimes
based on published analytical methods, which also explains the current limited
availability of TDM for TB drugs. Clearly more complex, labour-intensive assays de-
veloped ‘in house’ hinder the inter-laboratory comparability of drug measurements
and definitely require participation in an external QC programme.
Unfortunately an international interlaboratory QC programme is as yet unavailable
for TB drugs. We therefore started such an external QC programme, focusing on
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first-line as well as several second-line TB drugs.
TB drugs involved in the first round of the QC programme were isoniazid, rifampi-
cin, pyrazinamide, ethambutol (first-line TB drugs), moxifloxacin and linezolid
(second-line TB drugs). All raw drug substances were of analytical quality and had
a high and specified purity (> 99%). TB drugs were weighed out on independently
calibrated balances and dissolved in methanol/water using calibrated pipettes
and volumetric flasks. Drug-free human serum was obtained from the regional
blood bank. Blank serum was spiked with solutions of TB drugs to obtain two QC
samples. Each of the two samples contained all six TB drugs in either a low or
intermediate/high concentration (Table 4.1). The QC samples were freeze-dried
immediately in view of the instability of some of the drugs and to decrease shipping
costs. We had previously assessed stability under various conditions after freeze-

















































































Table 4.1: Measurements of quality control samples, subdivided by drug and concentration level. Data are
presented as median (range) unless otherwise stated. Conc.: concentration; int.: intermediate.
1 Low and Int./High conc. levels were 0.48 and 6.47 mg/L (isoniazid), 1.41 and 5.60 mg/L (rifampicin), 18.79 and
58.61 mg/L (pyrazinamide), 0.93 and 4.78 mg/L (ethambutol) , 0.31 and 2.65 mg/L (moxifloxacin), and 0.91 and
11.09 mg/L (linezolid). 2 Inaccuracy is the percentage bias from the true conc., i.e. inaccuracy = (100 * meas-
ured conc. / true conc.) - 100%. 3 Acceptable measurements are within 20% limits from the true conc.
4 Mean (range).
Seven laboratories from two continents participated in the first round of the pro-
gramme. The freeze-dried QC samples were transported at room temperature to
these laboratories. The laboratories were informed that the samples had to be
stored at 4 – 8 °C after receipt. They were requested to reconstitute the samples
with 1 ml water and to analyze them as soon as possible. Reconstituted samples
could also be stored at –80 °C for analysis at a later time point. The participating
laboratories were asked to return their results within 6 weeks after dispatch of the
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samples.
Descriptive statistics were calculated after standardization of all laboratory results
to percentages with reference to the true value. By subtracting 100% from these
percentages, the percentage bias from the true concentration (inaccuracy) was
calculated. 20% limits around the true values were considered to be appropriate
threshold values for satisfactory measurements, as used and justified in our other
international QC programmes [12] [13]. All participants were informed about their
performance within 2 months after reporting of their results.
Two of the seven participating laboratories were able to measure all six TB drugs,
one laboratory measured five drugs (all four first-line TB drugs and moxifloxa-
cin), two laboratories measured four drugs (all four first-line TB drugs, but not
the second-line drugs moxifloxacin and linezolid) and the two remaining laborat-
ories were able to measure less than four of the first-line drugs. Analytical meth-
odology used was conventional high-performance liquid chromatography, ultra-
performance liquid chromatography, liquid chromatography with mass spectro-
metric detection or gas chromatography with mass spectrometric detection.
A total of 58 analyses were performed, with satisfactory (accurate) results reported
for 48 (83%) measurements. Table 4.1 summarizes the results by TB drug. Ri-
fampicin concentrations were too low in three laboratories both at the low and
medium/high concentration. Furthermore, the programme showed ethambutol
concentrations that were too high for one laboratory, a trend for higher concentra-
tions of pyrazinamide in one participating laboratory, and similarly high concen-
trations of rifampicin in another laboratory.
The concentration level did not appear to affect accuracy, as 24 (83%) out of 29 of the
measurements was performed satisfactorily both at the low and intermediate/high
concentration levels .
When arranged by performing laboratory, it appeared that three out of seven labor-
atories performed all measurements within 20% inaccuracy limits (i.e. a 100%
score, 12 out of 12, 10 out of 10 and two out of two accurate results, respectively).
The other laboratories measured 10 out of 12 (83%), four out of six (67%), five out of
eight (63%) and five out of eight (63%) of the concentrations within the acceptance
limits.
83% of the measurements were within 20% limits of the true weighed-in concentra-
tions, meaning the initial results of this QC programme show a reasonably good
performance of the participating laboratories in measuring TB drugs. For com-
parison, first rounds of similar programmes for antiretroviral drugs and antifungal
drugs yielded satisfactory measurements in 65% and 77% of the measurements,
respectively [12, 13]. One out of six (17%) measurements of TB drugs was still inac-
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curate and such figures are relevant in the context of pharmacokinetic studies and
TDM. In this respect, it should be recognised that the first round of this programme
may have selected the best-performing laboratories or those with emphasis on
quality assurance.
The results for rifampicin in this first round were clearly worse than for other drugs.
We have wondered whether these results might be due to incomplete dissolution of
the freeze-dried samples, as rifampicin is slightly soluble in aquous solutions. For
the next rounds we will validate the dissolution of the samples once more.
Beyond the possible QC programme problems, many other sources of error may
explain the rifampicin results, including method (validation) problems, equipment,
technical and clerical errors, as well as unexplained errors [11]. In the past we have
evaluated such possible sources of error in other QC programmes by sending an
error evaluation form to the laboratories; this will be considered for future rounds
of the TB programme.
It is worth noting that low rifampicin serum or plasma concentrations have been
reported by many authors in populations all over the world. Based on the results
of this first round of the QC programme, it can not be excluded that some of these
findings may be explained by inaccuracy in the measurement of rifampicin, yet
the results of the first round of this programme should not be overinterpreted and
results from subsequent rounds should be awaited.
Many research consortia are currently studying the effects of higher doses of ri-
fampicin, and resulting in higher exposures achieved with these doses, both in
pulmonary and extrapulmonary TB. This emphasises the relevance of accurate
assays for rifampicin and the usefulness of this QC programme.
In addition to the low rifampicin concentrations measured in some laboratories,
the programme revealed possible inaccuracies or previously undetected problems
related to analysis of ethambutol and pyrazinamide in some laboratories. By parti-
cipating in the programme, these laboratories were alerted to these problems, and
this may enable and encourage them to optimise their methods and intralaboratory
QC procedures. Clearly, this is how external QC control testing aims to achieve
improvement in laboratory performance and attain interconvertibility of results
between laboratories [9, 11].
For the first round of the programme, we selected all first-line TB drugs (group I of
TB drugs), moxifloxacin as a pivotal representative from group III of TB drugs
(fluoroquinolones) [14] and linezolid because this drug is frequently used for
multidrug-resistant/extensively drug-resistant TB treatment despite its allocation
to group V of TB drugs [10, 15]. In future rounds of the programme, we will consider
incorporating other TB drugs (with consideration of the requests of the participants)
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and offer two patient casus in relation to the measurements, for those involved
in TDM for TB drugs. An increase in the number of participants may allow for an
evaluation of the effects of the drug measured, the concentration level or analytical
methodology on the accuracy of the results and will provide a better impression of
overall laboratory performance.
In summary, external QC for measurement of TB drugs in serum or plasma is pivotal
considering the high level of interest in the pharmacokinetics of TB drugs, both
for the development of new TB regimens and for direct applications in patient
care (TDM). We have developed an interlaboratory (external) QC programme or
proficiency testing programme for TB drugs and invite laboratories to participate
in this programme.
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